ArticleDiagnostics (Basel, Switzerland)2015
Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT.
Article in Diagnostics (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.Molecular imaging and biology · 2020Pooled it
- DoesEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Evaluating response to radium-223 usingAnnals of nuclear medicine · 2025Article
- Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?Frontiers in medicine · 2023Review
- A Retrospective Comparative Study of Sodium Fluoride NaLife (Basel, Switzerland) · 2022Article
- Beyond the Prognostic Value of 2-[Diagnostics (Basel, Switzerland) · 2022Review
- Review
- Interim and end-treatmentScientific reports · 2021Article
- Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer.International journal of molecular sciences · 2021Review
- A Retrospective Comparative Study of Sodium Fluoride (NaF-18)-PET/CT and Fluorocholine (F-18-CH) PET/CT in the Evaluation of Skeletal Metastases in Metastatic Prostate Cancer Using a Volumetric 3-D Radiomics Analysis.Diagnostics (Basel, Switzerland) · 2020Article
- Recent updates and developments in PET imaging of prostate cancer.Abdominal radiology (New York) · 2020Review
- Prognostic Value ofBiomedicines · 2020Article
- Article
- Review
- Article
- The potential ofEuropean journal of nuclear medicine and molecular imaging · 2017Article
- Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.Prostate cancer and prostatic diseases · 2017Article
- Therapy assessment of bone metastatic disease in the era ofEuropean journal of nuclear medicine and molecular imaging · 2017Review
- Advances in medical imaging for the diagnosis and management of common genitourinary cancers.Urologic oncology · 2017Review
- [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].Der Urologe. Ausg. A · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to evaluate the outcome after Radium-223-dichloride ((223)RaCl₂) treatment of patients with skeletal metastases of castration resistant prostate cancer using whole-body (18)F-Fluoride PET/CT. Sodium (18)F-fluoride [(18)F]-NaF PET/CT was performed prior the treatment of (223)RaCl₂, after the first cycle and after the sixth cycle. The skeletal metastases were analyzed quantitatively using modified PET response evaluation PERCIST criteria. The patients were also analyzed for S-PSA. All ten patients responded in [(18)F]-NaF scans after 6 cycles, but interim analysis after the 1st cycle did not give additional information about the outcome. The S-PSA decrease correlated with [(18)F]-NaF response, only 1 patient demonstrated progressive disease, i.e., >25% increase in S-PSA values during (223)RaCl₂. Our results (although preliminary) suggest that (18)F-Fluoride PET/CT is useful in the follow-up of castration resistant prostate cancer with skeletal metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.